Aurinia Pharmaceuticals Welcomes Craig Johnson To Board For Next Growth Phase

Aurinia Pharmaceuticals Inc. announced the addition of Craig Johnson to its Board of Directors as the company passes through the growth curve. Craig has served for over 30 years in significant senior financial roles in companies in the biotech industry. He has been a member of boards in Ardea Biosciences, Adamis Pharmaceuticals, Decipher Biosciences, La Jolla Pharmaceutical, Odonate Therapeutics, and Mirati Therapeutics. He is a member of the Heron Therapeutics board. Besides this, Aurinia announced today the retirement of Dr. Robert T. Foster from the Board.

“As part of our ongoing efforts to ensure that the Board includes the most qualified professionals to help guide the Company to maximise shareholder value, we welcome Craig to the Board. The Board would also like to thank Robert for his many contributions to the Company,” stated Kevin Tang, Chair of the Board.